LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

SCHEDULE 13G/A - Prenetics Global Ltd (0001876431) (Subject)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K/A - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ:PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024. Prenetics' Chief Executive Officer Danny Yeung and Chief Financial Officer Stephen Lo will present virtually on Wednesday, November 13th at 8:30 a.m. ET. A link to the webcast can be accessed through the investor section of the Company's website at https://ir.prenetics.com/. Additionally, management will be available for one-on-one investor meetings on Wednesday, November 13th. To schedule a one-on-one meeting with Prenetics' management, please conta

HONG KONG, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta at US$200 million and underscores Tencent's endeavor to advancing AI-powered innovations in healthcare. Following the transaction, Prenetics' stake in Insighta will be reduced from 50% to 35%. Insighta's co-founders will retain their 50% shareholding. As part of the agreement, Prenetics has received US$30 million in cash from the sale of secondary shares to Tencent, boosting its pro forma cash and other c

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2024, along with recent business updates. First Quarter 2024 Financial Highlights Revenue from continuing operations of US$6.4 million in the first quarter 2024, an increase of 30.2% as compared to the first quarter 2023.Gross p

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and implement a capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight how Prenetics is at the forefront of cutting-edge technological advancements in health and wellness. Under the Prenetics umbre

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates. Financial Highlights Revenue from continuing operations of US$21.7 million in the full year 2023, an increase of 65.2% as compared to the full year 2022.Revenue from continuing operations of US$5.4 million in the fourth quarter 2023, an increase of 90.8% as compared to the fourth quarter 2022.Adjusted EBITDA from continuing operations of US$(24.8) million in the full year 2023.Adjuste

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates. Third Quarter 2023 Financial Highlights Revenue from continuing operations of US$4.9 millionAdjusted EBITDA from continuing operations of US$(6.4) millionCash and other short-term assets1 of US$105.2 million as of September 30, 2023; with an additional $79.1 million of cash with Insighta, our 50/50 joint venture in early cancer detection with Professor Dennis Lo "During the third quarter, we made further pro

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and implement a capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight how Prenetics is at the forefront of cutting-edge technological advancements in health and wellness. Under the Prenetics umbre

(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government. - By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.1 - Prof. Dennis Lo is the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong (CUHK) and the Scientific Director of the Centre for Novostics. HONG KONG, June 25, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leadi

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology marketAcquisition expected to complete on or around December 30, 2022, subject to normal closing conditions LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PR

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $9.47875000 per share on the company’s 5.250% fixed-to-floating rate non-cumulative preferred stock, Series C, with a liquidation preference of $1,000 per share. Semi-annual dividend of $29.375 per share on the company’s 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company’s 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary

NEW YORK--(BUSINESS WIRE)--Two Harbors Investment Corp. (NYSE: TWO), an Agency + MSR mortgage real estate investment trust, today announced the redemption of all outstanding shares of both the company’s 7.75% Series D Cumulative Redeemable Preferred Stock (NYSE: TWO PRD)(the “Series D Preferred Stock”) and 7.50% Series E Cumulative Redeemable Preferred Stock (NYSE: TWO PRE)(“Series E Preferred Stock”). The cash redemption amount (the “Redemption Amount”) for each share of Series D Preferred Stock and Series E Preferred Stock is $25.00 plus accrued and unpaid dividends to, but not including, the redemption date for each series of March 15, 2021 (the “Redemption Date”). On the Redemp

On Thursday, Prenetics Global Limited (NASDAQ:PRE) announced that former international footballer, entrepreneur, and philanthropist David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on consumer health products, with details to be announced at a later date. Beckham said, “Throughout my life and career, I’ve been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That’s why I am excited to be working with Prenetics—a company dedicated to innovative, world-

Prenetics, (NASDAQ:PRE) a leading health sciences company, is proud to announce that former international footballer, entrepreneur and philanthropist David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on cutting-edge consumer health products, with details to be announced at a later date.Beckham said, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts and fitness coaches. Their guidance has been crucial to my health and well-being. That's why I am excited to be working with Prenetics - a company that i

Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(0.70) per share. This is a 44 percent increase over losses of $(1.25) per share from the same period last year. The company reported $6.41 million in sales this quarter. This is a 30.25 percent increase over sales of $4.92 million the same period last year.

Gainers GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. InnovAge Holding (NASDAQ:INNV) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. Mustang Bio (NASDAQ:MBIO) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. Seelos Therapeutics (NASDAQ:SEEL) shares increased by 4.88% to $0.29. The market

Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million. Prenetics Global (NASDAQ:PRE) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $70.4 million. Alterity Therapeutics (NASDAQ:ATHE) stock rose 15.02% to $2.45. The market value of their outstanding shares is at $21.3 million. Immutep (NASDAQ:IMMP) shares increased by 13.54% to $2.85. The market value of their outstanding shares is at $338.8 million. CareMax (NASDAQ:CMAX) shares rose 12.89% to $3.94. The market value of their outstanding shares is at $14.9 million. SINTX Techs (NASDAQ:SINT) stock moved

Cantor Fitzgerald analyst Ross Osborn maintains Prenetics Global (NASDAQ:PRE) with a Overweight and lowers the price target from $10 to $9.

Prenetics Global (NASDAQ:PRE) reported its Q4 earnings results on Monday, April 1, 2024 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Prenetics Global beat estimated earnings by 32.0%, reporting an EPS of $-0.51 versus an estimate of $-0.75. Revenue was down $46.89 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day. Here's a look at Prenetics Global's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.05 -0.75 0.9 -1.5 EPS Actual -0.05 -0.75 -0.6 0.9 Revenue Estimate 18.14M 25.98M 24.20M 54.97M

Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.75) by 32 percent. This is a 139.23 percent decrease over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $5.43 million which missed the analyst consensus estimate of $17.60 million by 69.16 percent. This is a 90.84 percent increase over sales of $2.84 million the same period last year.